Intellectual Property Rights (IPRs) over life materials—such as genetically modified microorganisms, cell lines, isolated DNA sequences, and gene-editing tools—are central to modern biotechnology, pharmaceutical innovation, and agriculture, governed globally under the WTO TRIPS Agreement and the Budapest Treaty.

Present World Scenario of IPR on Life Materials

• Expansion of Patentability in Developed Jurisdictions: Led by the United States following Diamond v. Chakrabarty (1980), advanced economies permit broad patenting of genetically modified organisms, synthetic biology constructs, and gene-editing methods (e.g., commercial CRISPR-Cas9 patents).
• Ethical and Public Order Limitations (Article 27.3(b) of TRIPS): Allows member states to exclude plants, animals, and essential biological processes from patentability, while requiring protections for microorganisms and plant varieties (via patents or a sui generis system).
• Protection of Traditional Knowledge Against Biopiracy: Developing nations utilize mechanisms like the Convention on Biological Diversity (CBD) and the Nagoya Protocol on Access and Benefit Sharing (ABS) to protect indigenous biological knowledge from misappropriation, supported in India by the Traditional Knowledge Digital Library (TKDL).
• India’s Balanced Statutory Safeguards: Under Section 3(j) of the Indian Patents Act, 1970, plants, animals, seeds, and essential biological processes are non-patentable, while plant varieties are protected separately under the PPV&FR Act, 2001. Section 3(d) prevents trivial modifications of known substances, protecting public health access.

Reasons for Low Commercialisation of Patents in India

• Weak Industry-Academia Linkages: Academic research in universities and national laboratories often focuses on publishing papers and filing patents to meet institutional metrics, without adequate private industry collaboration to develop market-ready products.
• The “Valleys of Death” in Early-Stage Financing: Indian startups and researchers face capital gaps in transitioning laboratory discoveries through proof-of-concept, pilot prototyping, and clinical trial validations.
• Limited Specialized R&D Infrastructure: Developing life materials requires advanced biosafety laboratories, cleanrooms, and testing facilities that are capital-intensive and less accessible outside premier institutions.
• Regulatory Complexity and Long Approvals: Clearances involving the Genetic Engineering Appraisal Committee (GEAC), clinical trials, and bio-safety reviews involve multi-tiered procedures that can delay commercial product entry.
• Gaps in Technology Transfer Offices (TTOs): Indian universities often lack specialized IP management offices skilled in patent valuation, commercial licensing, and market development.

Way Forward

• Scale up commercialization support programs like the Biotechnology Industry Research Assistance Council (BIRAC) to fund proof-of-concept development.
• Establish professional Technology Transfer Offices across universities and simplify single-window regulatory pathways for biotechnology innovations.

India’s patent volume highlights growing research capacity. Connecting laboratory research with venture funding, industry partnerships, and streamlined regulations is essential to convert patents into commercial innovations.